

# Financial Tear Sheet

## Corporate Profile

Perseon is dedicated to developing innovative technologies to fight cancer. Our products treat soft tissue tumors with precision-focused microwave energy, expanding treatment options for patients and healthcare providers everywhere. Backed by a seasoned executive team, we are a market leader in energy ablation, generating growing revenue from our proprietary MicroThermX® line of products.

## Primary IR Contact

Tricia Ross


Phone: 310-622-8226

E-mail:

[TRoss@finprofiles.com](mailto:TRoss@finprofiles.com)

## Stock Performance

<b>PRSN (Common Stock)</b>	
Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	<b>\$0.07</b>
Change (%)	▼ 0.02 (22.22%)
Volume	148,680
52 Week High	\$7.50
52 Week Low	\$0.07
Market Cap	\$644,577
Rolling EPS	-2.53
PE Ratio	0
Shares Outstanding	9,766,323



Data as of 01/15/16 4:00 p.m. ET

## Recent Headlines

12/22/15

[Galil Medical Tender Offer to Acquire Perseon Corporation Expires](#)

---

11/30/15

[Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call](#)

---

10/27/15

[Galil Medical Enters Into Agreement to Acquire Perseon Corporation to Create Leader in Ablation Treatment for Tumors](#)

---

## SEC Filings

Filing Date	Form
04/27/17	15-12G
01/24/17	EFFECT
01/24/17	EFFECT
01/24/17	EFFECT

## Upcoming Events

There are currently no events scheduled.

## Corporate Governance

<a href="#">William S. Barth</a>	Chief Financial Officer
<a href="#">Todd H. Turnlund</a>	VP of Research & Design
<a href="#">Jennifer Hoglin</a>	Vice President of Global Marketing
<a href="#">Ben Beckham</a>	Vice President of Global Sales
<a href="#">Brian A. Meltzer, M.D.</a>	Chief Medical Officer and Vice President of Business Development
<a href="#">Rick Gaykowski</a>	Vice President of Regulatory, Quality, and Clinical Affairs

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Perseon 2015.